SRR4296092
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- TNFA_SIGNALING_VIA_NFKB+0.350
- CHOLESTEROL_HOMEOSTASIS+0.320
- OXIDATIVE_PHOSPHORYLATION+0.320
- ALLOGRAFT_REJECTION+0.310
- MYC_TARGETS_V1+0.290
- DNA_REPAIR+0.280
- INFLAMMATORY_RESPONSE+0.280
- MTORC1_SIGNALING+0.260
Top 10 suppressed
- ANDROGEN_RESPONSE-0.350
- PROTEIN_SECRETION-0.350
- ANGIOGENESIS-0.310
- UV_RESPONSE_DN-0.300
- MITOTIC_SPINDLE-0.200
- APICAL_SURFACE-0.130
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.100
- FATTY_ACID_METABOLISM-0.100
- TGF_BETA_SIGNALING-0.100
- KRAS_SIGNALING_UP-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BT-A42F-01A-11R-A23W-07 | — | — | 0.749 |
| 2 | cddceb59-733b-48d1-9b75-46c9949f7794 | — | — | 0.746 |
| 3 | MNG413 | — | — | 0.740 |
| 4 | MNG1266 | — | — | 0.730 |
| 5 | 64a608f6-9848-4c97-820d-d87f9ee04a7b | — | — | 0.724 |
| 6 | BS_VF5XWFXD | high-grade glioma | — | 0.716 |
| 7 | 131e315e-6653-4199-b653-42b81644dad9 | — | — | 0.712 |
| 8 | 46C5EF69-5EAF-4FBA-BE47-28A8E7F3D9A2 | — | — | 0.708 |
| 9 | SRR33346940 | — | — | 0.705 |
| 10 | TCGA-BH-A0HB-01A-11R-A056-07 | — | B | 0.701 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |